Brainstorm Cell Therapeutics (BCLI) Short Interest Ratio & Short Volume $1.61 -0.05 (-3.01%) Closing price 03:59 PM EasternExtended Trading$1.66 +0.05 (+3.04%) As of 07:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Brainstorm Cell Therapeutics Short Interest DataBrainstorm Cell Therapeutics (BCLI) has a short interest of 91,400 shares, representing 2.06% of the float (the number of shares available for trading by the public). This marks a -47.17% decrease in short interest from the previous month. The short interest ratio (days to cover) is 0.9, indicating that it would take 0.9 days of the average trading volume of 48,887 shares to cover all short positions.Current Short Interest91,400 sharesPrevious Short Interest173,000 sharesChange Vs. Previous Month-47.17%Dollar Volume Sold Short$166,348.00Short Interest Ratio0.9 Days to CoverLast Record DateJanuary 31, 2025Outstanding Shares5,700,000 sharesFloat Size4,430,000 sharesShort Percent of Float2.06%Today's Trading Volume19,525 sharesAverage Trading Volume48,887 sharesToday's Volume Vs. Average40% Short Selling Brainstorm Cell Therapeutics? Sign up to receive the latest short interest report for Brainstorm Cell Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartBCLI Short Interest Over TimeBCLI Days to Cover Over TimeBCLI Percentage of Float Shorted Over Time Brainstorm Cell Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 1/31/202591,400 shares $166,348.00 -47.2%2.1%0.9 $1.82 1/15/2025173,000 shares $354,650.00 +85.4%3.9%1.7 $2.05 12/31/202493,300 shares $211,791.00 -38.8%2.1%0.8 $2.27 12/15/2024152,400 shares $220,980.00 +2.8%3.1%1.4 $1.45 11/30/2024148,200 shares $257,868.00 -14.8%3.0%1.6 $1.74 11/15/2024173,900 shares $210,419.00 +58.4%3.6%2.3 $1.21 10/31/2024109,800 shares $205,326.00 -33.8%2.3%1.7 $1.87 10/15/2024165,900 shares $351,708.00 +33.2%3.4%3.6 $2.12 9/30/2024124,600 shares $28,695.38 -91.1%2.6%3.6 $0.23 9/15/20241,400,000 shares $394,800.00 +8.5%N/A3.2 $0.28 Get the Latest News and Ratings for BCLI and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Brainstorm Cell Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/31/20241,290,000 shares $398,610.00 -20.4%N/A2.4 $0.31 8/15/20241,620,000 shares $507,384.00 +51.4%N/A2.9 $0.31 7/31/20241,070,000 shares $366,154.00 -0.9%N/A1.9 $0.34 7/15/20241,080,000 shares $450,360.00 -26.5%N/A1.8 $0.42 6/30/20241,470,000 shares $497,595.00 +65.1%N/A1.9 $0.34 6/15/2024890,600 shares $418,582.00 -20.5%N/A1 $0.47 5/31/20241,120,000 shares $544,992.00 -20.6%N/A1.2 $0.49 5/15/20241,410,000 shares $682,440.00 -32.9%N/A1.4 $0.48 4/30/20242,100,000 shares $792,750.00 +5.5%N/A2.1 $0.38 4/15/20241,990,000 shares $1.09 million +48.5%N/A2 $0.55 3/31/20241,340,000 shares $756,698.00 +57.6%N/A1.3 $0.56 3/15/2024850,300 shares $283,064.87 -20.5%N/A0.6 $0.33 2/29/20241,070,000 shares $392,690.00 -13.0%N/A0.7 $0.37 2/15/20241,230,000 shares $477,240.00 -39.4%N/A0.5 $0.39 1/31/20242,030,000 shares $717,199.00 -15.1%N/A0.8 $0.35 1/15/20242,390,000 shares $781,291.00 -43.2%N/A0.9 $0.33 12/31/20234,210,000 shares $1.15 million +25.3%N/A1.5 $0.27 12/15/20233,360,000 shares $789,600.00 -4.0%N/A0.9 $0.24 11/30/20233,500,000 shares $976,500.00 -7.2%N/A1.1 $0.28 11/15/20233,770,000 shares $689,910.00 +5.6%N/A1.6 $0.18 10/31/20233,570,000 shares $546,210.00 -20.5%9.8%1.9 $0.15 10/15/20234,490,000 shares $763,300.00 +1.1%12.4%2.6 $0.17 9/30/20234,440,000 shares $888,444.00 +26.1%12.2%3 $0.20 9/15/20233,520,000 shares $3.39 million +9.3%9.7%9.3 $0.96 8/31/20233,220,000 shares $5.51 million +21.1%9.2%13.4 $1.71 8/15/20232,660,000 shares $4.15 million No Change7.6%11.3 $1.56 7/31/20232,660,000 shares $4.89 million -5.3%8.6%12 $1.84 7/15/20232,810,000 shares $5.54 million +0.4%9.1%12.1 $1.97 6/30/20232,800,000 shares $5.77 million +2.9%9.1%11.7 $2.06 6/15/20232,720,000 shares $7.37 million -5.6%8.8%6.7 $2.71Now that Trump’s be inaugurated, this day will be key (mark your calendar) (Ad)Mark your calendar for March 13th. Because on that day, I believe we could see a $2 Trillion shock INTO the market… Unleashing more explosive moves than ever before.So please watch this video now before the hammer falls and it’s too late. 5/31/20232,880,000 shares $8.21 million +0.4%9.6%7.2 $2.85 5/15/20232,870,000 shares $7.92 million -9.2%9.5%8 $2.76 4/30/20233,160,000 shares $9.13 million +7.9%11.3%7.8 $2.89 4/15/20232,930,000 shares $8.23 million -5.5%10.4%7.3 $2.81 3/31/20233,100,000 shares $10.23 million +29.7%11.0%7.7 $3.30 3/15/20232,390,000 shares $3.87 million +0.8%8.5%10.2 $1.62 2/28/20232,370,000 shares $5.36 million +3.0%8.4%10.6 $2.26 2/15/20232,300,000 shares $5.24 million +18.6%8.1%9.6 $2.28 1/31/20231,940,000 shares $3.53 million -1.5%6.9%7 $1.82 1/15/20231,970,000 shares $2.88 million -3.9%7.0%8.3 $1.46 12/30/20222,050,000 shares $3.36 million -9.3%7.3%8.9 $1.64 12/15/20222,260,000 shares $4.09 million No Change8.0%9.6 $1.81 11/30/20222,260,000 shares $3.73 million -12.4%8.0%8.8 $1.65 11/15/20222,580,000 shares $4.46 million -4.1%9.1%9.8 $1.73 10/31/20222,690,000 shares $9.58 million +10.3%9.5%11.1 $3.56 10/15/20222,440,000 shares $8.49 million +23.2%8.7%10.2 $3.48 9/30/20221,980,000 shares $8.75 million +52.3%7.0%8.9 $4.42 9/15/20221,300,000 shares $5.59 million +68.2%4.6%7.2 $4.30 8/31/2022772,900 shares $2.80 million +36.6%2.7%5.3 $3.62 8/15/2022565,900 shares $1.95 million -5.4%2.0%4.8 $3.45 7/31/2022598,200 shares $1.53 million +3.1%2.1%9.8 $2.56 7/15/2022580,300 shares $1.53 million -9.5%3.2%9.5 $2.64 6/30/2022641,300 shares $1.77 million -0.1%3.6%10.7 $2.76 6/15/2022642,100 shares $1.83 million -4.9%3.6%10.2 $2.85 5/31/2022675,200 shares $1.99 million +5.6%2.4%10.6 $2.94 5/15/2022639,600 shares $1.74 million +6.6%2.3%9.7 $2.72 4/30/2022600,200 shares $1.80 million -2.1%2.1%9.1 $3.00 4/15/2022612,800 shares $1.93 million -8.5%2.2%8.6 $3.15 3/31/2022669,400 shares $2.25 million -8.4%2.4%8.4 $3.36 3/15/2022731,100 shares $2.30 million -0.6%2.6%5.1 $3.15 2/28/2022735,200 shares $2.24 million -7.0%2.6%2.4 $3.05 2/15/2022790,200 shares $2.47 million -22.5%2.8%2.1 $3.12 1/31/20221,020,000 shares $3.18 million -9.7%3.3%2.5 $3.12 1/15/20221,130,000 shares $4.01 million -17.5%3.6%2.7 $3.55 12/31/20211,370,000 shares $5.48 million +11.4%4.4%3.3 $4.00 12/15/20211,230,000 shares $4.05 million +32.1%3.9%3.3 $3.29 11/30/2021931,500 shares $3.54 million +27.1%3.1%4.2 $3.80 11/15/2021732,900 shares $2.23 million -1.4%2.4%4.8 $3.04 10/29/2021743,600 shares $2.16 million -11.5%2.5%6.3 $2.90 10/15/2021839,800 shares $2.59 million -14.4%2.8%5.9 $3.08 9/30/2021981,000 shares $3.24 million +6.8%3.3%6.6 $3.30 9/15/2021918,700 shares $3.24 million -11.7%3.1%4.1 $3.53 8/31/20211,040,000 shares $3.61 million No Change3.5%4.3 $3.47 8/13/20211,040,000 shares $3.83 million +16.3%3.5%3.5 $3.68 7/30/2021894,200 shares $3.60 million -32.3%3.0%2.7 $4.03 7/15/20211,320,000 shares $4.51 million -5.7%4.4%3.6 $3.42 6/30/20211,400,000 shares $5.32 million -60.9%4.7%3.4 $3.80 6/15/20213,580,000 shares $14.21 million +0.3%11.9%6.3 $3.97 5/28/20213,570,000 shares $12.78 million -18.5%11.9%5.8 $3.58 5/14/20214,380,000 shares $14.10 million +14.7%N/A6 $3.22Now that Trump’s be inaugurated, this day will be key (mark your calendar) (Ad)Mark your calendar for March 13th. Because on that day, I believe we could see a $2 Trillion shock INTO the market… Unleashing more explosive moves than ever before.So please watch this video now before the hammer falls and it’s too late. 4/30/20213,820,000 shares $13.41 million +4.1%N/A4.4 $3.51 4/15/20213,670,000 shares $12.92 million -16.4%N/A3.2 $3.52 3/31/20214,390,000 shares $16.29 million +4.0%N/A3.8 $3.71 3/15/20214,220,000 shares $18.06 million +7.4%N/A3.5 $4.28 2/26/20213,930,000 shares $15.60 million -6.9%N/A3.4 $3.97 2/12/20214,220,000 shares $30.00 million -9.4%N/A3.2 $7.11 1/29/20214,660,000 shares $29.38 million -2.9%N/A3.1 $6.31 1/15/20214,800,000 shares $24.05 million -11.1%N/A3.6 $5.01 12/31/20205,400,000 shares $25.00 million -15.2%N/A4.1 $4.63 12/15/20206,370,000 shares $33.06 million -5.9%N/A4.9 $5.19 11/30/20206,770,000 shares $35.54 million +5.5%N/A5.7 $5.25 11/15/20206,420,000 shares $74.79 million +7.5%N/A6.1 $11.65 10/30/20205,970,000 shares $64.18 million +17.5%N/A10.2 $10.75 10/15/20205,080,000 shares $84.79 million +12.1%N/A8.4 $16.69 9/30/20204,530,000 shares $76.65 million +18.3%N/A8.7 $16.92 9/15/20203,830,000 shares $54.19 million -1.5%N/A6 $14.15 8/31/20203,890,000 shares $49.05 million +8.1%N/A5.5 $12.61 8/14/20203,600,000 shares $47.77 million +2.9%N/A4.8 $13.27 7/31/20203,500,000 shares $47.43 million -20.8%N/A4.8 $13.55 7/15/20204,420,000 shares $57.15 million No ChangeN/A6.3 $12.93 6/30/20204,420,000 shares $49.02 million +39.9%N/A7 $11.09 6/15/20203,160,000 shares $31.41 million +12.1%N/A5.8 $9.94 5/29/20202,820,000 shares $18.78 million -4.4%N/A5.2 $6.66 5/15/20202,950,000 shares $16.37 million +12.2%N/A4.7 $5.55 4/30/20202,630,000 shares $16.38 million +14.9%N/A3.2 $6.23 4/15/20202,290,000 shares $12.89 million +22.5%10.8%3 $5.63 3/31/20201,870,000 shares $11.35 million +69.5%8.8%2.6 $6.07 3/13/20201,103,400 shares $5.62 million +3.1%5.9%1.9 $5.09 2/28/20201,070,000 shares $4.94 million +40.8%5.8%2 $4.62 BCLI Short Interest - Frequently Asked Questions What is Brainstorm Cell Therapeutics' current short interest? Short interest is the volume of Brainstorm Cell Therapeutics shares that have been sold short but have not yet been closed out or covered. As of January 31st, traders have sold 91,400 shares of BCLI short. 2.06% of Brainstorm Cell Therapeutics' shares are currently sold short. Learn More on Brainstorm Cell Therapeutics' current short interest. What is a good short interest ratio for Brainstorm Cell Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. BCLI shares currently have a short interest ratio of 1.0. Learn More on Brainstorm Cell Therapeutics's short interest ratio. Which institutional investors are shorting Brainstorm Cell Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Brainstorm Cell Therapeutics: Citadel Advisors LLC, and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Brainstorm Cell Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 2.06% of Brainstorm Cell Therapeutics' floating shares are currently sold short. Is Brainstorm Cell Therapeutics' short interest increasing or decreasing? Brainstorm Cell Therapeutics saw a decrease in short interest in the month of January. As of January 31st, there was short interest totaling 91,400 shares, a decrease of 47.2% from the previous total of 173,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Brainstorm Cell Therapeutics' float size? Brainstorm Cell Therapeutics currently has issued a total of 5,700,000 shares. Some of Brainstorm Cell Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Brainstorm Cell Therapeutics currently has a public float of 4,430,000 shares. How does Brainstorm Cell Therapeutics' short interest compare to its competitors? 2.06% of Brainstorm Cell Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Brainstorm Cell Therapeutics: Iterum Therapeutics plc (5.32%), RAPT Therapeutics, Inc. (7.35%), PepGen Inc. (2.57%), Tempest Therapeutics, Inc. (6.56%), Precision BioSciences, Inc. (20.79%), Clene Inc. (2.44%), Elevation Oncology, Inc. (16.86%), Annovis Bio, Inc. (13.56%), CASI Pharmaceuticals, Inc. (0.77%), Alterity Therapeutics Limited (6.35%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.21 billion), Charter Communications, Inc. ($4.07 billion), Reddit, Inc. ($3.33 billion), The Kroger Co. ($2.67 billion), Cencora, Inc. ($2.29 billion), Hims & Hers Health, Inc. ($2.17 billion), SoFi Technologies, Inc. ($1.99 billion), Live Nation Entertainment, Inc. ($1.87 billion), Rivian Automotive, Inc. ($1.76 billion), and Moderna, Inc. ($1.60 billion). View all of the most shorted stocks. What does it mean to sell short Brainstorm Cell Therapeutics stock? Short selling BCLI is an investing strategy that aims to generate trading profit from Brainstorm Cell Therapeutics as its price is falling. BCLI shares are trading down $0.05 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Brainstorm Cell Therapeutics? A short squeeze for Brainstorm Cell Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of BCLI, which in turn drives the price of the stock up even further. How often is Brainstorm Cell Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including BCLI, twice per month. The most recent reporting period available is January, 31 2025. More Short Interest Resources from MarketBeat Related Companies Iterum Therapeutics Short Interest Data RAPT Therapeutics Short Interest Data PepGen Short Interest Data Tempest Therapeutics Short Interest Data Precision BioSciences Short Interest Data Clene Short Interest Data Elevation Oncology Short Interest Data Annovis Bio Short Interest Data CASI Pharmaceuticals Short Interest Data Alterity Therapeutics Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:BCLI) was last updated on 2/25/2025 by MarketBeat.com Staff From Our PartnersBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Brainstorm Cell Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Brainstorm Cell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.